← Back to Search

Other

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers (COG0107 Trial)

Phase 1
Waitlist Available
Research Sponsored by Cognition Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 13 and 15.
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a drug called CT1812 in 36 older healthy volunteers. Researchers want to see how the drug behaves in their bodies, including how it is absorbed and broken down. Participants will stay at a research unit for a short period to receive the drug and undergo various tests. CT1812 is a new treatment being tested for its safety in healthy volunteers.

Eligible Conditions
  • Alzheimer's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 13 and 15.
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 13 and 15. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF)- CSF/plasma ratio
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Pharmacokinetics (PK) in plasma

Side effects data

From 2023 Phase 2 trial • 16 Patients • NCT04735536
19%
Procedural headache
13%
Nausea
13%
Hematoma
13%
Headache
6%
Paraesthesia
6%
Diarrhea
6%
Hepatic enzyme increased
6%
Corona virus infection
6%
Blood creatinine increased
6%
Atrial fibrillation
6%
Bone contusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
CT1812

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: 300 mg QDExperimental Treatment1 Intervention
CT1812 300 mg QD
Group II: 150 mg QDExperimental Treatment1 Intervention
CT1812 150 mg QD
Group III: 150 mg BIDExperimental Treatment1 Intervention
CT1812 150 mg BID
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CT1812
2020
Completed Phase 2
~330

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Cognition TherapeuticsLead Sponsor
11 Previous Clinical Trials
1,254 Total Patients Enrolled
Anthony Caggiano, MDStudy DirectorCognition Therapeutics
4 Previous Clinical Trials
831 Total Patients Enrolled
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top